about
Redox activation of metal-based prodrugs as a strategy for drug deliveryAn Organometallic Inhibitor for the Human Repair Enzyme 7,8-Dihydro-8-oxoguanosine TriphosphataseBioactive cyclometalated phthalimides: design, synthesis and kinase inhibitionNon-ATP-Mimetic Organometallic Protein Kinase InhibitorRuthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozymeChiral ruthenium(II) polypyridyl complexes: stabilization of g-quadruplex DNA, inhibition of telomerase activity and cellular uptakeElemental and chemically specific X-ray fluorescence imaging of biological systemsOrganometallic Half-Sandwich Dichloridoruthenium(II) Complexes with 7-Azaindoles: Synthesis, Characterization and Elucidation of Their Anticancer Inactivity against A2780 Cell Line.Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumorsOxoaporphine Metal Complexes (CoII, NiII, ZnII) with High Antitumor Activity by Inducing Mitochondria-Mediated Apoptosis and S-phase Arrest in HepG2.Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK SignalingMetal complexes as potential modulators of inflammatory and autoimmune responses.1-(2-Picolyl)-substituted 1,2,3-triazole as novel chelating ligand for the preparation of ruthenium complexes with potential anticancer activity.Characterization of aziridinylbenzoquinone DNA cross-links by liquid chromatography-infrared multiphoton dissociation-mass spectrometry.Excellent correlation between drug release and portal size in metalla-cage drug-delivery systems.Ru binding to RNA following treatment with the antimetastatic prodrug NAMI-A in Saccharomyces cerevisiae and in vitroLibrary of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier.Nitro/nitrosyl-ruthenium complexes are potent and selective anti-Trypanosoma cruzi agents causing autophagy and necrotic parasite deathImpact of low- and high-molecular-mass components of human serum on NAMI-A binding to transferrin.Anticancer Activity of Self-Assembled Molecular Rectangles via Arene-Ruthenium Acceptors and a New Unsymmetrical Amide LigandAnticancer activities of self-assembled molecular bowls containing a phenanthrene-based donor and Ru(II) acceptors.Comparison of KP1019 and NAMI-A in tumour-mimetic environments.Revisiting oxo-centered carbonyl-triruthenium clusters: investigating CO photorelease and some spectroscopic and electrochemical correlations.Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor CellsIn vitro effects of novel ruthenium complexes in Neospora caninum and Toxoplasma gondii tachyzoites.Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.Metal-based anti-diabetic drugs: advances and challenges.Targeted and multifunctional arene ruthenium chemotherapeutics.Inductively coupled plasma-MS in drug development: bioanalytical aspects and applications.Anticancer metallodrug research analytically painting the "omics" picture--current developments and future trends.The use of X-ray absorption and synchrotron based micro-X-ray fluorescence spectroscopy to investigate anti-cancer metal compounds in vivo and in vitro.Novel lead structures and activation mechanisms for CO-releasing molecules (CORMs)Enhancing vascular relaxing effects of nitric oxide-donor ruthenium complexes.Combination of ICP-MS, capillary electrophoresis, and their hyphenation for probing Ru(III) metallodrug-DNA interactions.Metallomics: the history over the last decade and a future outlook.Ruthenium-based nitric oxide-donating and carbon monoxide-donating molecules.Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.Studies on Photocleavage, DNA Binding, Cytotoxicity, and Docking Studies of Ruthenium(II) Mixed Ligand Complexes.A ruthenium(ii) based photosensitizer and transferrin complexes enhance photo-physical properties, cell uptake, and photodynamic therapy safety and efficacy.Solvent assisted formation of ruthenium(III) and ruthenium(II) hydrazone complexes in one-pot with potential in vitro cytotoxicity and enhanced LDH, NO and ROS release.
P2860
Q27025736-2EFF52FD-BC00-4A78-BC45-D59AF8F0DADBQ27680660-31E26CA5-8A54-4177-8F58-4CBD8C7C0AE7Q27681382-C5E691F0-02C8-464F-BF84-EAFB7B1AFDE0Q27681838-5615A934-067E-4629-A4DF-D72061107739Q27689147-7A680E03-BF41-4861-A392-2AA1ED01F72CQ28484250-3D380BB6-F084-498D-8972-92E9E2868103Q28655858-E11A857F-D09A-4376-9A4B-1B7FDD66EB1DQ31028118-B965A730-19D1-4C5B-8BAC-90979D317A75Q33553649-6DAA98F1-570B-463C-8613-2DE716FF63C4Q33594393-C42A98BF-C2EF-4FD9-A7D8-4F0F1D905F40Q33754805-AF40DD3A-2411-47C4-8F3F-54048E795EB3Q33805225-2539B41B-8F54-4C90-B2CF-923AF9C5F6EAQ33862825-63CA757A-7332-44B9-ACA7-6F80865FDB3FQ33936414-89116AA0-1E2E-462A-8CFF-498092171063Q33953543-94263FE6-B703-4C7D-8603-7B1CF08E7643Q33955538-A6187276-B80D-4128-9EE7-C009554CE8B5Q33991566-57C2BA84-7E97-4191-B929-FCA0A0388B31Q34299137-08019F69-DDBB-41E9-A782-B54FB508FC3CQ35621511-B11F03DA-6905-4051-AFCB-67E724443233Q35983960-D3065B3D-0CC0-4604-9E52-D7B73B8A9B4AQ36010364-2275148E-4406-4580-9CCB-7A3ACE26DB68Q36086603-18954DCA-8520-40C5-9C8C-62032AF6130CQ36173658-F1358377-E60A-4A4E-BA20-A566D6496297Q36499563-0F83C7BF-1638-4CA6-8133-8BB679DC98ABQ37263372-2C651FFF-2F7E-488F-B8FD-2B967A429412Q37724010-9B497DA6-EF12-4B87-9A67-78845B56A310Q37900507-652C8A8D-C5F4-4123-86A9-F914319F8D77Q37920741-AE3FFFA3-AA4B-4026-A5E5-E2EB87C89A09Q38040178-471864AF-6AA2-4C62-8D33-9456E344FCA7Q38052406-7D3A4D66-DCA6-4E04-9515-0A02B93516F8Q38096196-E8FAE026-8C17-48A1-A07E-19F91B5BF087Q38195891-71FD1EE1-C06B-426B-9221-958E8C88E60FQ38221279-8B3A5EF8-4EDA-4C99-B0ED-75D7A2BD6FFCQ38289334-860BFC04-FBF1-4488-AAD1-2445B0977B8EQ38649441-A338ED3A-BB7E-4518-AF05-196B6340C660Q38698568-5ED6E6EE-4738-4BE6-9F2D-4D6C45D1A59EQ38699445-E8DBD912-1A59-440D-B302-A6F175C0E98AQ38735217-9C30E913-DA14-4B9A-8858-4CC7583CD08FQ38788535-772FEA56-B152-43CE-82CA-0ACADC6D7C4BQ38809475-0CDAF5C0-8300-497F-B51C-C3EF4E898984
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent developments in ruthenium anticancer drugs.
@en
Recent developments in ruthenium anticancer drugs.
@nl
type
label
Recent developments in ruthenium anticancer drugs.
@en
Recent developments in ruthenium anticancer drugs.
@nl
prefLabel
Recent developments in ruthenium anticancer drugs.
@en
Recent developments in ruthenium anticancer drugs.
@nl
P2860
P356
P1433
P1476
Recent developments in ruthenium anticancer drugs.
@en
P2093
Anannya Mitra
Aviva Levina
P2860
P304
P356
10.1039/B904071D
P50
P577
2009-08-13T00:00:00Z